Efficacy and tolerability of eperisone versus tizanidine in patients suffering from low back pain with muscle spasm

Author:

Khan Abdul F.,Parveen Khaneta,Khan Abdul S.

Abstract

Background: Low back pain (LBP), a high prevalent condition, is usually associated with 'muscle spasm' that is responsible for giving rise to pain. Eperisone hydrochloride is widely used for treatment associated muscle stiffness and pain. The aim of the study was to compare the efficacy and safety of eperisone tablets 50 mg three times daily versus tizanidine 2 mg tablets thrice daily for the treatment of low back pain with muscle spasm.Methods: The study was carried in 50 patients from a private hospital at Mumbai. Only patients satisfying the inclusion criteria were enrolled into the study. Subjects suffering from low back pain with spasm were divided in two groups. The patients were then followed up on Day-14.Results: Patients receiving eperisone showed a mean value of 16.48±1.15 in the Roland Morris low back pain and disability questionnaire both groups on day 1 and was reduced to 7.92±1.15 (51.94%) on day 7 and 2.56±1.53 (84.46%) on day 14. Similarly, the patients in tizanidine group had mean value of 15.96±1.62 on day 1, which was reduced to 6.76±1.66 (57.64%) on day 7, and 2.88±1.92 (81.95%) on day 14, as similar to eperisone group. There was no statistical significant difference between the two groups, (p>0.05) for pain at rest, pain at night, restriction of movement, changes in stiffness, changes in numbness and changes in tenderness. There was statistical significant difference between the two groups, (p<0.05) for pain on movement and kinesalgia.Conclusions: Eperisone was found to be comparable to Tizanidine in improving the signs and symptoms of changes in pain Self-assessment by the patient on different applied parameters.

Publisher

Medip Academy

Subject

General Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3